[{"address1": "601 Gateway Boulevard", "address2": "Suite 900", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "(650) 457-1978", "website": "https://structuretx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 111, "maxAge": 86400, "priceHint": 2, "previousClose": 46.75, "open": 46.68, "dayLow": 44.64, "dayHigh": 46.72, "regularMarketPreviousClose": 46.75, "regularMarketOpen": 46.68, "regularMarketDayLow": 44.64, "regularMarketDayHigh": 46.72, "forwardPE": -56.25926, "volume": 711883, "regularMarketVolume": 711883, "averageVolume": 942824, "averageVolume10days": 1230640, "averageDailyVolume10Day": 1230640, "bid": 45.46, "ask": 45.76, "bidSize": 400, "askSize": 300, "marketCap": 2599681792, "fiftyTwoWeekLow": 25.57, "fiftyTwoWeekHigh": 75.017, "fiftyDayAverage": 41.1912, "twoHundredDayAverage": 45.857, "currency": "USD", "enterpriseValue": 5942249472, "floatShares": 115425043, "sharesOutstanding": 57048100, "sharesShort": 4112192, "sharesShortPriorMonth": 4114099, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.088199995, "heldPercentInsiders": 0.04557, "heldPercentInstitutions": 0.813, "shortRatio": 8.73, "shortPercentOfFloat": 0.1093, "impliedSharesOutstanding": 46386400, "bookValue": 9.22, "priceToBook": 4.9425163, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -97681000, "trailingEps": -2.25, "forwardEps": -0.81, "enterpriseToEbitda": -51.819, "52WeekChange": 0.3132565, "SandP52WeekChange": 0.26238096, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "GPCR", "underlyingSymbol": "GPCR", "shortName": "Structure Therapeutics Inc.", "longName": "Structure Therapeutics Inc.", "firstTradeDateEpochUtc": 1675434600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "8fb71ef4-0d7a-30de-b9f4-2631f9206cd7", "messageBoardId": "finmb_1673457818", "gmtOffSetMilliseconds": -14400000, "currentPrice": 45.57, "targetHighPrice": 100.0, "targetLowPrice": 65.0, "targetMeanPrice": 85.11, "targetMedianPrice": 91.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 9, "totalCash": 436448992, "totalCashPerShare": 3.121, "ebitda": -114673000, "totalDebt": 5125000, "quickRatio": 18.505, "currentRatio": 19.052, "debtToEquity": 1.192, "returnOnAssets": -0.20427, "returnOnEquity": -0.29326, "freeCashflow": -61888124, "operatingCashflow": -93260000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]